Delle Cave Donatella, Rizzo Riccardo, Sainz Bruno, Gigli Giuseppe, Del Mercato Loretta L, Lonardo Enza
Institute of Genetics and Biophysics "A. Buzzati-Traverso", National Research Council (CNR-IGB), Via Pietro Castellino 111, 80131 Naples, Italy.
Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100 Lecce, Italy.
Cancers (Basel). 2021 Feb 23;13(4):930. doi: 10.3390/cancers13040930.
Pancreatic cancer, the fourth most common cancer worldwide, shows a highly unsuccessful therapeutic response. In the last 10 years, neither important advancements nor new therapeutic strategies have significantly impacted patient survival, highlighting the need to pursue new avenues for drug development discovery and design. Advanced cellular models, resembling as much as possible the original in vivo tumor environment, may be more successful in predicting the efficacy of future anti-cancer candidates in clinical trials. In this review, we discuss novel bioengineered platforms for anticancer drug discovery in pancreatic cancer, from traditional two-dimensional models to innovative three-dimensional ones.
胰腺癌是全球第四大常见癌症，其治疗反应极不理想。在过去十年中，无论是重大进展还是新的治疗策略，都未对患者生存率产生显著影响，这凸显了探索新的药物研发途径的必要性。尽可能类似于原始体内肿瘤环境的先进细胞模型，可能在预测未来抗癌候选药物在临床试验中的疗效方面更具成效。在本综述中，我们讨论了用于胰腺癌抗癌药物发现的新型生物工程平台，从传统的二维模型到创新的三维模型。
